CD274 and T-cell non-Hodgkin lymphoma: This approach has improved outcomes in B-cell malignancies when combined with rituximab [38], obinutuzumab [39], and daratumumab [40] and is now being evaluated with the anti-PD-L1 monoclonal antibody durvalumab in T-cell lymphomas [41].